Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.

The Journal of molecular diagnostics : JMD - 1 Mar 2010

Brevet Marie, Arcila Maria, Ladanyi Marc

Abstract excerpt

EGFR mutations are the best predictors of response to EGFR kinase inhibitors in lung adenocarcinoma. We evaluated two mutation-specific monoclonal antibodies for the detection of EGFR mutations by immunohistochemistry (IHC), generated respectively against the L858R mutant and the exon 19 mutant w...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Amino Acid Sequence
Share to Antibodies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gene Deletion

Share to Immunohistochemistry

Share to Lung Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 20093391
DOI: 10.2353/jmoldx.2010.090140
PMCID: PMC2871723

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20093391-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.PMID 20093391Read ↗

Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma.Semantic proximity Read ↗

EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.Semantic proximity Read ↗

Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma.Semantic proximity Read ↗

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.Semantic proximity Read ↗

Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma.Semantic proximity Read ↗

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.Semantic proximity Read ↗

Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.Semantic proximity Read ↗

Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma.Semantic proximity Read ↗

Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.Semantic proximity Read ↗

A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.Semantic proximity Read ↗

Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer.Semantic proximity Read ↗

EGFR mutation-specific antibodies in pulmonary adenocarcinoma: a comparison with DNA direct sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.